Pharmaceuticals FDA Grants Orphan Drug Designation to MabWell’s Small Cell Lung Cancer Treatment Last updated: July 23, 2024 8:13 pm By bexib 0 Min Read Share SHARE The novel drug 7MW3711 binds to tumor cell membrane antigens, is internalized and transported to lysosomes, and releases cytotoxic drugs to induce tumor cell apoptosis. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article SAAR 16.1 million, up 1% from the previous year Next Article Lily Beach Resort Wins Wine Spectator Award of Excellence for 2024 – Hotel Maldives Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Upskilling: An interview with Steph Piper Manufacturing Young Kiwis toast change: hazardous drinking falls by 13% in five years Hospitality & Tourism Clearview FCU saves 6,000 labor hours through RPA Banking Inside Varo Bank’s GEN AI Copilot build Banking